GRI Bio Financials
| GRI Etf | USD 0.66 0.03 4.76% |
GRI |
The data published in GRI Bio's official financial statements typically reflect GRI Bio's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving GRI Bio's quantitative information. For example, before you start analyzing numbers published by GRI accountants, it's essential to understand GRI Bio's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
GRI Bio Etf Summary
GRI Bio competes with Werewolf Therapeutics, Edgewise Therapeutics, Celcuity LLC, C4 Therapeutics, and Shattuck Labs. The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 92023M101 3622AW106 3622AW304 3622AW205 |
| Region | Others |
| Investment Issuer | Others |
| Location | Pennsylvania; U.S.A |
| Business Address | 2223 Avenida de |
| Etf Family | Biotechnology |
| Fund Category | Others |
| Portfolio Concentration | Others |
| Benchmark | Dow Jones Industrial |
| Website | www.gribio.com |
| Phone | 619 400 1170 |
| Currency | USD - US Dollar |
GRI Bio Key Financial Ratios
GRI Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GRI Bio's current stock value. Our valuation model uses many indicators to compare GRI Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GRI Bio competition to find correlations between indicators driving GRI Bio's intrinsic value. More Info.GRI Bio is one of the top ETFs in price to earning as compared to similar ETFs. It is rated below average in price to book as compared to similar ETFs fabricating about 0.07 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for GRI Bio is roughly 14.57 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GRI Bio's earnings, one of the primary drivers of an investment's value.GRI Bio Systematic Risk
GRI Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GRI Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on GRI Bio correlated with the market. If Beta is less than 0 GRI Bio generally moves in the opposite direction as compared to the market. If GRI Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GRI Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GRI Bio is generally in the same direction as the market. If Beta > 1 GRI Bio moves generally in the same direction as, but more than the movement of the benchmark.
About GRI Bio Financials
What exactly are GRI Bio Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include GRI Bio's income statement, its balance sheet, and the statement of cash flows. Potential GRI Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although GRI Bio investors may use each financial statement separately, they are all related. The changes in GRI Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GRI Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.GRI Bio February 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of GRI Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GRI Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of GRI Bio based on widely used predictive technical indicators. In general, we focus on analyzing GRI Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GRI Bio's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 33.91 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 7.81 |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.